ColonoscopyNCT05754255
Comparison of High-flow Oxygen With or Without Nasal Positive Airway Pressure (PAP) During Propofol Sedation for Colonoscopy in an Ambulatory Surgical Center
A study testing Nasal Cannula and Nasal Positive Airway Pressure System in people with Colonoscopy and Positive-Pressure Respiration, run by Indiana University at 1 site in United States.
Trial summary
The primary objective of the prospective study is to compare the incidence, duration, and severity of oxygen desaturation in high-risk patients randomized to nasal mask with nasal positive airway pressure (PAP) or standard care (nasal cannula) receiving propofol sedation during colonoscopy in an ambulatory surgical… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colonoscopy, Positive-Pressure Respiration
- What is being tested?
- Nasal Cannula and Nasal Positive Airway Pressure System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2023to 3 Jun 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- Outpatients undergoing colonoscopy.
- American Society of Anesthesiology (ASA) Physical Status I-III
- BMI ≥35 kg/m2, documented obstructive sleep apnea or BMI>30 with STOP-BANG score ≥3
- Written informed consent
Who cannot join
- Inpatient status
- Active Congestive Heart Failure Exacerbation
- Untreated ischemic heart disease
- Acute exacerbation of respiratory disorders, including COPD and asthma
- Emergent procedures
- Pregnancy
Show all 19Show fewer
- Previous enrollment in this study
- Inability to provide informed consent.
- Additional medical testing planned for the same day.
- History of allergic reaction to propofol
- History of allergic reaction to polypropylene or PVC.
- Tracheostomy
- Supra-glottic or sub-glottic tumor
- Gastrointestinal tract obstruction or delayed transit (including delayed gastric emptying, gastric bezoar, achalasia, toxic megacolon).
- Known obstructing colon tumor, lesion, or stricture
- Previous colon surgery (excluding anal surgery)
- Active GI bleeding (hematochezia or melena during procedure preparation)
- Large polyp (> 2cm) removal
- Previous failed or unsuccessfully completed colonoscopy.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of High-flow Oxygen With or Without Nasal Positive Airway Pressure (PAP) During Propofol Sedation for Colonoscopy in an Ambulatory Surgical Center: a Prospective Randomized Controlled Trial
The primary objective of the prospective study is to compare the incidence, duration, and severity of oxygen desaturation in high-risk patients randomized to nasal mask with nasal positive airway pressure (PAP) or standard care (nasal cannula) receiving propofol sedation during colonoscopy in an ambulatory surgical center (ASC).
Patients will be randomized in groups of ten to one of two groups using a random number table.
Read more
Group A: standard care with a nasal cannula. Group B: SuperNO2VA™EtCO2. Following the procedure subjects will be asked to complete satisfaction surveys before leaving the ASC and 48 +/- hours following their procedure.
Researchers will compare levels of satisfaction and levels of oxygen saturation.
Read the detailed description
This study involves the oxygenation, continuous positive airway pressure, and ventilation of a subject via nasal mask and oxygenation via a closed facemask. The interventions directly related to this study are that of supplement oxygen, bag-mask ventilation, and continuous nasal CPAP intra-operatively and in the recovery unit.
Patients will be randomized in groups of ten to one of two groups using a random number table.
Group A: standard care with a nasal cannula. Group B: SuperNO2VA™EtCO2. For each anesthetic case, a preoperative history and physical and intraoperative record will be documented.
Once in the endoscopy suite, the patients will have baseline vital signs, EtCO2 and oxygen levels measured. Continuous monitoring of heart rate, end tidal CO2 (EtC02), O2 saturation, and every 3-minutes BP monitoring will be obtained. For patients randomized to group A, the anesthesia provider will supply oxygen via nasal cannula at 10LPM. For patients randomized to group B, the anesthesia provider will attach the SuperNO2VA™ EtCO2's circuit port to the hyperinflation bag with the oxygen flow rate to 10 L/min, and the adjustable pressure-limiting (APL) valve completely closed. Initial propofol bolus of 0.5-1.0 mg/kg actual body weight will be administered for sedation. No other sedative or analgesic will be permitted besides propofol. MOAA/S scores will be assessed by the anesthesiologist and medical team and recorded by the research assistant. If the patient's MOAA/S score is ≥ 4, additional 20-50 mg boluses will be administered every 30 - 90 seconds until a MOAA/S score <4 is reached. Once a MOAA/S <4 is reached the endoscopist will insert the colonoscope into the rectum. Sedation will be titrated to maintain a MOAA/S <4 throughout the procedure. If the patient's MOAA/S score ≥4, additional 20-50 mg boluses of propofol will be administered every 30-90 seconds until the MOAA/S is <4. The measurements recorded during colonoscopy for both groups will be: time of administration of sedation; incidence, severity, and duration of oxygen desaturation; number, duration and reason for performing the airway maneuver(s); duration of the procedure; total dose of medication; blood pressure, heart and respiratory rate, and oxygen saturation; time to full recovery; and patient cooperation. The research assistant will document their patient's depth of sedation, cooperation with procedure, and safety.
Endoscope techniques performed during the procedure such as biopsies, dilation, polypectomy, etc. will be tracked. Techniques to facilitate proximal passage of the endoscope such as moving the patient or abdominal pressure will also be noted. If the anatomic extent desired to complete the colonoscopy is not reached (i.e., colon stricture, excessive looping of the instrument), then the patient will be withdrawn from the study.
Patients will recover in the endoscopy suite. The patients will have continuous monitoring of heart rate, end tidal CO2 (EtC02), O2 saturation, and every 5-minute BP monitoring and MOAAS Score. Once a MOAAS score of 5 is obtained, the patient will be offered to drink independently unless deemed inappropriate by the treating physician(s). The endoscopist when available will discuss findings with the patient and/or family, the patient will then dress and leave the endoscopy suite when possible. The time to discharge will be obtained for each patient. Patients will also complete a satisfaction and pain questionnaire before discharge. Subjects will be sent surveys to complete at 48 hours post discharge, concerning their satisfaction and their subjective degree of impairment due to the sedation. They will have the option to complete this electronically via a link to REDCap or with a self-addressed envelope and paper form of the survey. If the patients do not complete or send back their questionnaire, someone will contact them by telephone to collect the data. A statistician using student T-test, Fishers exact test, and other statistical methods they deem appropriate will analyze the collected data.
- Conditions
- Colonoscopy, Positive-Pressure Respiration
- Being tested
- Nasal Cannula, Nasal Positive Airway Pressure System
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nasal CannulaDevice
A nasal cannula is a medical device to provide supplemental oxygen therapy to people who have lower oxygen levels. There are two types of nasal cannulas: low flow and high flow.
The device has two prongs and sits below the nose. The two prongs deliver oxygen directly into your nostrils.
Nasal Positive Airway Pressure SystemDevice
Also called Nasal CPAP
Positive airway pressure (PAP) treatment uses a machine to pump air under pressure into the airway of the lungs. This helps keep the windpipe open during sleep. The forced air delivered by CPAP (continuous positive airway pressure) prevents episodes of airway collapse that block the breathing in people with obstructive sleep apnea and other breathing problems.
| Study group | Role | What they receive |
|---|---|---|
| Group A: standard care with a nasal cannula. | Active comparator | Group A will be given the standard nasal cannula during sedation. The cannula prongs will be inserted into the patient's nose to provide oxygen to the patient. Receives: Device: Nasal Cannula |
| Group B: SuperNO2VA™EtCO2 | Active comparator | Group B will be given a nasal oxygen to deliver gas, create a seal, and provide positive pressure. The mask will be placed over a patient's nose and connected to either an anesthesia circuit or hyperinflation bag during respiratory, anesthesia, and resuscitation procedures. Receives: Device: Nasal Positive Airway Pressure System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of desaturation
Compare incidence of desaturation of Nasal PAP Versus Nasal Administration of Oxygen
Measured: 60 minutes
Duration of oxygen desaturation
Compare the duration of desaturation of Nasal PAP Versus Nasal Administration of Oxygen
Measured: 60 minutes
Severity of oxygen desaturation
Compare the severity of desaturation of Nasal PAP Versus Nasal Administration of Oxygen
Measured: 60 minutes
Secondary outcomes (21)
Total Amount of Propofol for Adequate Sedation
Compares amounts of Propofol for induction and entire procedure administered for procedure
Measured: 60 minutes
Modified Observer's Assessment of Alertness/Sedation Scale
Compare Modified Observer's Assessment of Alertness/Sedation Scale (MOAAS) scores immediately prior to endoscope insertion and during the procedure.
MOAAS scale is 0-5, where 0=No response after painful stimuli and 5 Responds to name spoken in normal tone. Patients with a MOAAS <4 are considered to be moderately to deeply sedated. The greater the degree of sedation the greater the degree of respiratory depression.
Measured: 60 minutes
Endoscope Insertion
Compare the length of time from induction to endoscope insertion.
Measured: 60 minutes
Incidence of Airway maneuvers
Compare the number of incidence of airway maneuvers
Measured: 60 minutes
Duration of Airway maneuvers
Compare the duration for airway maneuvers
Measured: 60 minutes
Patient Satisfaction
Compare patient satisfaction scores (visual analog scale (VAS)) immediately after procedure.
VAS range is from 0= Not at all satisfied to 5=Completely satisfied.
Measured: 48 hours
Reason(s) for airway maneuvers
Compare reason(s) for airway maneuvers as reported by anesthesiologist via open ended interview in real time.
Measured: 60 minutes
Incidence of any desaturation
Compare the incidence of any oxygen desaturation <85% between the start and end of sedation.
Measured: 60 Minutes
Frequency of Oxygen Saturation
Compare the frequency of oxygen saturation saturation <85% over 15 seconds between the start and end of sedation.
Measured: 60 minutes
Frequency of bradycardia
Compare the frequency of bradycardia (HR<45 bpm)between the start and end of sedation.
Measured: 60 minutes
Frequency of low respiratory rate
Compare the frequency of low respiratory rate (<6 per minute between the start and end of sedation.
Measured: 60 minutes
Use of endotracheal intubation
Compare the use of endotracheal intubation as airway management in patient population.
Measured: 60 minutes
Use of Noninvasive positive pressure ventilation
Compare the use of noninvasive positive pressure ventilation as airway management in patient population during sedation.
Measured: 60 minutes.
Use of pharmacological blood pressure support
Compare the use of pharmacological blood pressure support from the start and end of sedation.
Measured: 60 minutes.
Incidence of hospitilization
Compare the incidence of hospitalization following sedation for a colonoscopy in patient population.
Measured: 48 hours
Serious Adverse Events
Compare incidence of adverse events from start of sedation to 48 hours following the end of sedation.
Measured: 48 hours
Frequency of Procedural Interruption
Compare the frequency of the removal of endoscope due to a respiratory complication from start to end of sedation.
Measured: 60 minutes
Duration of Procedural Interruption
Compare the duration of endoscope removal due to a respiratory complication from start of sedation to end of sedation.
Measured: 60 minutes.
Length of Procedure
Compare the length of time for procedure from start of sedation to end of sedation.
Measured: 60 minutes
Ready to discharge
Compare the length of time from end of sedation to ready to discharge
Measured: 30 min
Time to discharge
Compare the length of time from end of sedation to actual discharge.
Measured: 90 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2023
- Study startSep 2023 (estimated)
- Primary completion1 Jun 2024 (estimated)
- Study completion3 Jun 2024 (estimated)
Why it stopped: No available resources.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ColonoscopyStudies of the same condition, open and under way.
- More trials run by Indiana UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Indiana University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, John DeWitt, Indiana University
- Investigators
- John DeWitt, MD, Principal investigator, Professor of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05754255
- Sponsor's protocol ID
- 17675
- Status last verified
- Jul 2024
- First submitted
- 31 Dec 2022
- Last updated
- 24 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of High-flow Oxygen With or Without Nasal Positive Airway Pressure (PAP) During Propofol Sedation for Colonoscopy in an Ambulatory Surgical Center: a Prospective Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05754255
- Acronym / sponsor ID
- 17675
- Conditions
- Colonoscopy, Positive-Pressure Respiration
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: No available resources.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Indiana UniversityUniversity, hospital or other
- Study start
- Sep 2023 (estimated)
- Primary completion
- 1 Jun 2024 (estimated)
- Study completion
- 3 Jun 2024 (estimated)
- First posted
- 3 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of the prospective study is to compare the incidence, duration, and severity of oxygen desaturation in high-risk patients randomized to nasal mask with nasal positive airway pressure (PAP) or standard care (nasal cannula) receiving propofol sedation during colonoscopy in an ambulatory surgical center (ASC).
Patients will be randomized in groups of ten to one of two groups using a random number table.
Group A: standard care with a nasal cannula. Group B: SuperNO2VA™EtCO2. Following the procedure subjects will be asked to complete satisfaction surveys before leaving the ASC and 48 +/- hours following their procedure.
Researchers will compare levels of satisfaction and levels of oxygen saturation.
Detailed description
This study involves the oxygenation, continuous positive airway pressure, and ventilation of a subject via nasal mask and oxygenation via a closed facemask. The interventions directly related to this study are that of supplement oxygen, bag-mask ventilation, and continuous nasal CPAP intra-operatively and in the recovery unit.
Patients will be randomized in groups of ten to one of two groups using a random number table.
Group A: standard care with a nasal cannula. Group B: SuperNO2VA™EtCO2. For each anesthetic case, a preoperative history and physical and intraoperative record will be documented.
Once in the endoscopy suite, the patients will have baseline vital signs, EtCO2 and oxygen levels measured. Continuous monitoring of heart rate, end tidal CO2 (EtC02), O2 saturation, and every 3-minutes BP monitoring will be obtained. For patients randomized to group A, the anesthesia provider will supply oxygen via nasal cannula at 10LPM. For patients randomized to group B, the anesthesia provider will attach the SuperNO2VA™ EtCO2's circuit port to the hyperinflation bag with the oxygen flow rate to 10 L/min, and the adjustable pressure-limiting (APL) valve completely closed. Initial propofol bolus of 0.5-1.0 mg/kg actual body weight will be administered for sedation. No other sedative or analgesic will be permitted besides propofol. MOAA/S scores will be assessed by the anesthesiologist and medical team and recorded by the research assistant. If the patient's MOAA/S score is ≥ 4, additional 20-50 mg boluses will be administered every 30 - 90 seconds until a MOAA/S score <4 is reached. Once a MOAA/S <4 is reached the endoscopist will insert the colonoscope into the rectum. Sedation will be titrated to maintain a MOAA/S <4 throughout the procedure. If the patient's MOAA/S score ≥4, additional 20-50 mg boluses of propofol will be administered every 30-90 seconds until the MOAA/S is <4. The measurements recorded during colonoscopy for both groups will be: time of administration of sedation; incidence, severity, and duration of oxygen desaturation; number, duration and reason for performing the airway maneuver(s); duration of the procedure; total dose of medication; blood pressure, heart and respiratory rate, and oxygen saturation; time to full recovery; and patient cooperation. The research assistant will document their patient's depth of sedation, cooperation with procedure, and safety.
Endoscope techniques performed during the procedure such as biopsies, dilation, polypectomy, etc. will be tracked. Techniques to facilitate proximal passage of the endoscope such as moving the patient or abdominal pressure will also be noted. If the anatomic extent desired to complete the colonoscopy is not reached (i.e., colon stricture, excessive looping of the instrument), then the patient will be withdrawn from the study.
Patients will recover in the endoscopy suite. The patients will have continuous monitoring of heart rate, end tidal CO2 (EtC02), O2 saturation, and every 5-minute BP monitoring and MOAAS Score. Once a MOAAS score of 5 is obtained, the patient will be offered to drink independently unless deemed inappropriate by the treating physician(s). The endoscopist when available will discuss findings with the patient and/or family, the patient will then dress and leave the endoscopy suite when possible. The time to discharge will be obtained for each patient. Patients will also complete a satisfaction and pain questionnaire before discharge. Subjects will be sent surveys to complete at 48 hours post discharge, concerning their satisfaction and their subjective degree of impairment due to the sedation. They will have the option to complete this electronically via a link to REDCap or with a self-addressed envelope and paper form of the survey. If the patients do not complete or send back their questionnaire, someone will contact them by telephone to collect the data. A statistician using student T-test, Fishers exact test, and other statistical methods they deem appropriate will analyze the collected data.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A: standard care with a nasal cannula. | Active comparator | Device: Nasal CannulaGroup A will be given the standard nasal cannula during sedation. The cannula prongs will be inserted into the patient's nose to provide oxygen to the patient. |
| Group B: SuperNO2VA™EtCO2 | Active comparator | Device: Nasal Positive Airway Pressure SystemGroup B will be given a nasal oxygen to deliver gas, create a seal, and provide positive pressure. The mask will be placed over a patient's nose and connected to either an anesthesia circuit or hyperinflation bag during respiratory, anesthesia, and resuscitation procedures. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥18 years
- Outpatients undergoing colonoscopy.
- American Society of Anesthesiology (ASA) Physical Status I-III
- BMI ≥35 kg/m2, documented obstructive sleep apnea or BMI>30 with STOP-BANG score ≥3
- Written informed consent
Key exclusion criteria (19 listed)
- Inpatient status
- Active Congestive Heart Failure Exacerbation
- Untreated ischemic heart disease
- Acute exacerbation of respiratory disorders, including COPD and asthma
- Emergent procedures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nasal CannulaA nasal cannula is a medical device to provide supplemental oxygen therapy to people who have lower oxygen levels. There are two types of nasal cannulas: low flow and high flow. The device has two prongs and sits below the nose. The two prongs deliver oxygen directly into your nostrils. | Device | Group A: standard care with a nasal cannula. |
| Nasal Positive Airway Pressure SystemAlso: Nasal CPAPPositive airway pressure (PAP) treatment uses a machine to pump air under pressure into the airway of the lungs. This helps keep the windpipe open during sleep. The forced air delivered by CPAP (continuous positive airway pressure) prevents episodes of airway collapse that block the breathing in people with obstructive sleep apnea and other breathing problems. | Device | Group B: SuperNO2VA™EtCO2 |
Primary outcome
Incidence of desaturation
Time frame: 60 minutes
Compare incidence of desaturation of Nasal PAP Versus Nasal Administration of Oxygen
Duration of oxygen desaturation
Time frame: 60 minutes
Compare the duration of desaturation of Nasal PAP Versus Nasal Administration of Oxygen
Severity of oxygen desaturation
Time frame: 60 minutes
Compare the severity of desaturation of Nasal PAP Versus Nasal Administration of Oxygen
21 secondary outcomes
Total Amount of Propofol for Adequate Sedation
Time frame: 60 minutes
Modified Observer's Assessment of Alertness/Sedation Scale
Time frame: 60 minutes
Endoscope Insertion
Time frame: 60 minutes
Incidence of Airway maneuvers
Time frame: 60 minutes
Duration of Airway maneuvers
Time frame: 60 minutes
Patient Satisfaction
Time frame: 48 hours
Reason(s) for airway maneuvers
Time frame: 60 minutes
Incidence of any desaturation
Time frame: 60 Minutes
Frequency of Oxygen Saturation
Time frame: 60 minutes
Frequency of bradycardia
Time frame: 60 minutes
Frequency of low respiratory rate
Time frame: 60 minutes
Use of endotracheal intubation
Time frame: 60 minutes
Use of Noninvasive positive pressure ventilation
Time frame: 60 minutes.
Use of pharmacological blood pressure support
Time frame: 60 minutes.
Incidence of hospitilization
Time frame: 48 hours
Serious Adverse Events
Time frame: 48 hours
Frequency of Procedural Interruption
Time frame: 60 minutes
Duration of Procedural Interruption
Time frame: 60 minutes.
Length of Procedure
Time frame: 60 minutes
Ready to discharge
Time frame: 30 min
Time to discharge
Time frame: 90 minutes
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2026.
Related trials for Colonoscopy
Not yet recruiting
Effect of Box Breathing Exercise on Anxiety, Pain, and Pulmonary Function Tests in Patients Undergoing Colonoscopy
Colonoscopy
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Not yet recruiting
HFNC vs Conventional Oxygen During Gastrocolonoscopy in Elderly Patients
Hypoxemia, Eldery People
Recruiting
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Recruiting
Visual Aids for Colonoscopy Preparation: A Prospective Study on Patient Understanding and Bowel Cleanliness in Colonoscopy Patients
The Effect of Audio-visual Aids on Bowel Cleanliness, Audiovisual Aids
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John DeWitt, MD principal investigator
Professor of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nasal Cannula and Nasal Positive Airway Pressure System in people with Colonoscopy and Positive-Pressure Respiration, run by Indiana University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 24 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of desaturation (time frame: 60 minutes). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2026.